225Ac-naxitamab / SERB Pharmaceuticals - LARVOL DELTA

111In/225Ac-Naxitamab: Theranostic anti-GD2 antibody in the management of Osteosarcoma - in-vitro evaluation (SNMMI 2025) - "The radiolabeling yield of 111In-Naxitamab was 99%; therefore, no further purification was needed. The specific activity was 27.75 MBq/nmol. The radiolabeling yield for 225Ac-Naxitamab was 30-40%, and after purification with a PD-10 column, radiochemical purity was 99%."

Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

111In/225Ac-Naxitamab: Theranostic anti-GD2 antibody in the management of Osteosarcoma - in-vitro evaluation (SNMMI 2025) - "The radiolabeling yield of 111In-Naxitamab was 99%; therefore, no further purification was needed. The specific activity was 27.75 MBq/nmol. The radiolabeling yield for 225Ac-Naxitamab was 30-40%, and after purification with a PD-10 column, radiochemical purity was 99%."

Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor